We are analyzing https://link.springer.com/article/10.1007/s40265-019-01083-3.

Title:
Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee | Drugs
Description:
Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®) is approved in the USA for the management of osteoarthritis (OA) pain of the knee and is administered as a single, 5 mL intra-articular (IA) injection. Although the therapeutic effects from IA corticosteroids are typically short-lived, triamcinolone acetonide ER is formulated in poly (lactic-co-glycolic acid) (PLGA) microspheres that slowly release triamcinolone acetonide in the synovium, enabling their prolonged presence in the joint. This reduces systemic exposure and lessens corticosteroid-related systemic adverse reactions, such as blood glucose elevations. In a 24-week, randomized, phase III clinical trial, triamcinolone acetonide ER 32 mg significantly improved mean average daily pain intensity in patients with knee OA relative to placebo, and pain, stiffness and physical function (according to WOMAC criteria) relative to placebo and triamcinolone acetonide crystalline suspension (CS). Triamcinolone acetonide ER was generally well tolerated, with a tolerability profile similar to that of triamcinolone acetonide CS and placebo. Findings from a single-arm phase IIIb study indicated that a repeat administration of triamcinolone acetonide ER may be similarly efficacious to an initial injection without having deleterious effects on cartilage or other aspects of joint structure. Thus, triamcinolone acetonide ER expands the treatment options available for the management of OA pain of the knee.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

acetonide, triamcinolone, knee, pain, patients, article, injection, osteoarthritis, study, phase, placebo, treatment, administration, week, google, scholar, weeks, efficacy, extendedrelease, single, intraarticular, iii, clinical, significant, systemic, trial, adp, drug, intensity, injections, baseline, data, table, cas, corticosteroids, significantly, studies, trials, scores, aes, plga, randomized, generally, similar, repeat, function, information, research, review, open,

Topics {✒️}

ultrasound-guided intra-articular injection extended-release microsphere-based formulation open-label safety study steroidal anti-inflammatory drugs single-arm phase iiib study produce anti-inflammatory responses treatment-emergent adverse reactions corticosteroid-related adverse reactions triamcinolone acetonide extended-release extended-release triamcinolone acetonide triamcinolone acetonide er appeared triamcinolone acetonide er 32 mg triamcinolone acetonide er compared 21-carboxy-6β-hydroxytriamcinolone acetonide triamcinolone acetonide cs groups hypothalamic-pituitary-adrenal axis extended-release microsphere formulation triamcinolone acetonide er treatment clinical trial registries/databases open-label study blood glucose elevations oa-specific womac instrument dose-ranging phase ii oligomeric poly-acid units triamcinolone extended-release article download pdf phase ii pharmacokinetics study post hoc analyses phase iii clinical trial index knee-related aes koos-qol scores compared triamcinolone acetonide er triamcinolone acetonide er triamcinolone acetonide er [28] privacy choices/manage cookies triamcinolone acetonide cs triamcinolone acetonide cs rapid drug efflux single administration phase iib single intra-articular dose extended-release formulation blood glucose levels daily rescue medication single intra-articular injection 6β-hydroxytriamcinolone acetonide related subjects open-label standard triamcinolone acetonide triamcinolone acetonide binds triamcinolone acetonide [measured

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
         description:Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®) is approved in the USA for the management of osteoarthritis (OA) pain of the knee and is administered as a single, 5 mL intra-articular (IA) injection. Although the therapeutic effects from IA corticosteroids are typically short-lived, triamcinolone acetonide ER is formulated in poly (lactic-co-glycolic acid) (PLGA) microspheres that slowly release triamcinolone acetonide in the synovium, enabling their prolonged presence in the joint. This reduces systemic exposure and lessens corticosteroid-related systemic adverse reactions, such as blood glucose elevations. In a 24-week, randomized, phase III clinical trial, triamcinolone acetonide ER 32 mg significantly improved mean average daily pain intensity in patients with knee OA relative to placebo, and pain, stiffness and physical function (according to WOMAC criteria) relative to placebo and triamcinolone acetonide crystalline suspension (CS). Triamcinolone acetonide ER was generally well tolerated, with a tolerability profile similar to that of triamcinolone acetonide CS and placebo. Findings from a single-arm phase IIIb study indicated that a repeat administration of triamcinolone acetonide ER may be similarly efficacious to an initial injection without having deleterious effects on cartilage or other aspects of joint structure. Thus, triamcinolone acetonide ER expands the treatment options available for the management of OA pain of the knee.
         datePublished:2019-03-08T00:00:00Z
         dateModified:2019-09-06T00:00:00Z
         pageStart:455
         pageEnd:462
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s40265-019-01083-3
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:79
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Julia Paik
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Sean T. Duggan
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Susan J. Keam
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
      description:Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®) is approved in the USA for the management of osteoarthritis (OA) pain of the knee and is administered as a single, 5 mL intra-articular (IA) injection. Although the therapeutic effects from IA corticosteroids are typically short-lived, triamcinolone acetonide ER is formulated in poly (lactic-co-glycolic acid) (PLGA) microspheres that slowly release triamcinolone acetonide in the synovium, enabling their prolonged presence in the joint. This reduces systemic exposure and lessens corticosteroid-related systemic adverse reactions, such as blood glucose elevations. In a 24-week, randomized, phase III clinical trial, triamcinolone acetonide ER 32 mg significantly improved mean average daily pain intensity in patients with knee OA relative to placebo, and pain, stiffness and physical function (according to WOMAC criteria) relative to placebo and triamcinolone acetonide crystalline suspension (CS). Triamcinolone acetonide ER was generally well tolerated, with a tolerability profile similar to that of triamcinolone acetonide CS and placebo. Findings from a single-arm phase IIIb study indicated that a repeat administration of triamcinolone acetonide ER may be similarly efficacious to an initial injection without having deleterious effects on cartilage or other aspects of joint structure. Thus, triamcinolone acetonide ER expands the treatment options available for the management of OA pain of the knee.
      datePublished:2019-03-08T00:00:00Z
      dateModified:2019-09-06T00:00:00Z
      pageStart:455
      pageEnd:462
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s40265-019-01083-3
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:79
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Julia Paik
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Sean T. Duggan
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Susan J. Keam
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:79
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Julia Paik
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Sean T. Duggan
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
      name:Susan J. Keam
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Springer, Auckland, New Zealand
      name:Springer, Auckland, New Zealand
      name:Springer, Auckland, New Zealand

External Links {🔗}(83)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

AOS
Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.14s.

LINK . SPRINGER . COM {}